Which longevity company is closest to FDA approval?

Can the FDA actually approve a human longevity drug today?

No human company is currently close to getting a drug approved for “aging” itself, because the FDA still evaluates these therapies through specific diseases rather than aging as a standalone indication.

That distinction controls the whole ranking. A company can be built around longevity biology while pursuing FDA approval for Alzheimer’s disease, pulmonary fibrosis, glaucoma or a rare pediatric condition. The label on the eventual medicine may never mention lifespan or biological age.

Life Biosciences is testing partial cellular reprogramming, one of the most radical attempts to reverse age-related cellular changes, but ER-100 is still in Phase 1. Longeveron’s laromestrocel has several randomized Phase 2 studies behind it, but its most advanced one missed its main goal in September 2026. Insilico Medicine has gone further on stage with rentosertib, which started a Phase 3 trial for idiopathic pulmonary fibrosis in China that month.

The FDA has also qualified no aging biomarker as a surrogate endpoint for an approval based on slowing aging. Biological-age clocks can strengthen the scientific case, but today a company still needs to show that patients with a recognized condition actually benefit.

Does Loyal become the obvious winner if dog longevity counts?

Yes. If veterinary longevity counts, Loyal is currently far closer to an FDA market authorization than any human longevity company.

LOY-002 is a daily pill being developed for dogs aged 10 and older. Loyal is using the FDA Center for Veterinary Medicine’s expanded conditional approval pathway, which can allow a veterinary drug onto the market before the full effectiveness package has been completed.

LOY-002 has cleared two of the three major technical sections needed for conditional approval. The FDA accepted Loyal’s reasonable-expectation-of-effectiveness package in 2025 and its target-animal safety package in early 2026. Loyal’s own tracker still shows manufacturing and chemistry in progress, and no approval decision has been announced.

In September 2026, Loyal said the FDA had also accepted reasonable-expectation-of-effectiveness evidence for LOY-003, its program for large and giant breeds. That widens the pipeline, but it does not complete the missing manufacturing section for LOY-002.

The company is also running STAY, a study of more than 1,300 dogs across about 70 veterinary practices designed to test whether LOY-002 extends healthy lifespan. That larger study matters for eventual full approval, but Loyal does not have to wait for the final survival result before a conditional launch becomes possible.

Conditional approval carries a real qualification: the effectiveness standard is lower than the one required for full approval. Yet a conditionally approved drug can legally be prescribed and sold while the company continues generating the evidence needed for full approval.

Which human longevity company is actually closest to FDA approval?

There is no clear single answer anymore. The ranking depends on whether you count trial stage, FDA designations or patient data, and each measure points to a different company.

By stage, Insilico leads: rentosertib is in Phase 3, but in China. By regulatory signal, Calico leads: fosigotifator has FDA Breakthrough Therapy Designation and EMA PRIME status in a rare disease, but only Phase 1b/2 data. By volume of randomized human data, Longeveron still has the most among pure-plays, but its lead HLHS trial missed its primary endpoint in September 2026.

The rest of the field is earlier. BioAge has two Phase 2 trials running for BGE-102. Cambrian has early human data and is preparing Phase 2 programs. Life Biosciences and Retro are in Phase 1. NewLimit remains preclinical. Companies sit anywhere from preclinical to Phase 3, and we cover which ones are pulling ahead in our report covering longevity.

Longeveron’s fall is the main reason the answer changed. Before September, it looked like a company one good Phase 2b readout away from a filing discussion. Now it needs the FDA to accept a case built on secondary endpoints, while it reviews strategic options.

Our read today: Calico and Insilico form the front group, with Longeveron just behind. None has a disclosed U.S. marketing application.

Company	Most advanced relevant program	Current position	Our read
Calico	Fosigotifator	Phase 1b/2, FDA Breakthrough Therapy, EMA PRIME	Strongest rare-disease contender
Insilico Medicine	Rentosertib	Phase 3 in IPF, in China; no U.S. registration path disclosed	Furthest along by stage, not a pure-play
Longeveron	Laromestrocel	Phase 2b missed primary endpoint; FDA meeting planned	Most human data, weakened path
BioAge	BGE-102	Two Phase 2 trials	Needs clinical proof-of-concept
Cambrian	ATX-304	Phase 1b completed, Phase 2 planned	Still early
Life Biosciences	ER-100	Phase 1, first data in 3 patients	First reprogramming program in humans
Retro Biosciences	RTR242	Phase 1	Early human development
NewLimit	Liver reprogramming program	Preclinical	Human trial planned next

Can Longeveron’s cardiac-event benefit overcome ELPIS II’s failed endpoint?

Not on its own. ELPIS II missed its primary endpoint, so any FDA filing would rest on secondary results the agency has not yet reviewed.

ELPIS II is a 40-patient randomized Phase 2b trial testing laromestrocel alongside surgery in babies with hypoplastic left heart syndrome, or HLHS. The program has Orphan Drug, Fast Track and Rare Pediatric Disease designations, and the trial is supported through the National Heart, Lung, and Blood Institute.

Longeveron reported topline results on 16 September 2026. The primary endpoint, change in right-ventricular ejection fraction at 12 months, showed no benefit: a difference of −0.7 percentage points, p=0.8336. The FDA had already told the company in 2026 that this endpoint was not enough to show efficacy and no longer saw ELPIS II as pivotal.

On 26 October 2026, Longeveron released further analyses. The prespecified secondary endpoint of major adverse cardiac events showed 8 events in the standard-care arm versus 1 in the treated arm, p=0.043. Total major cardiac events were 22 versus 3, a rate ratio of 0.16. In September, the company had reported an as-treated count of 19 versus 12 that was not statistically significant, and the two releases do not explain the gap between these counts.

The company plans to request an FDA meeting, with no date disclosed, and will present the data at the American Heart Association meeting in November 2026. In parallel, it started a strategic review and cost cuts in September, and in October hired Lucid Capital Markets to explore options including a potential business combination.

The cardiac-event signal is the most interesting thing to come out of the trial. But a small study, a missed primary endpoint and inconsistent event counts make another trial the more likely outcome than a quick filing.

Is Longeveron’s Alzheimer’s program actually a cleaner FDA route?

On paper, yes. It is now Longeveron’s most plausible remaining route, but it is further from a readout and has no funded trial.

The company completed the randomized CLEAR MIND Phase 2a study in 48 people with mild Alzheimer’s disease. The study was primarily designed around safety, but Longeveron also reported encouraging results across a composite clinical score and MRI measures of brain-volume loss.

The FDA subsequently granted laromestrocel Regenerative Medicine Advanced Therapy and Fast Track designations for mild Alzheimer’s disease.

During a Type B meeting, Longeveron says it reached tentative alignment with the FDA on the basic design of a single seamless adaptive Phase 2/3 study, including the patient population, dose, placebo arm, treatment duration and endpoints. According to the company’s SEC filings, the FDA also agreed to consider a BLA based on positive interim results from that study.

The problem is execution. Longeveron has been seeking a partner to fund the Alzheimer’s trial, and the ELPIS II miss has made that harder: the company is cutting costs and weighing strategic options. A clear design is not the same as a positive confirmatory study, and that study has not started.

Does Insilico’s Phase 3 in China put it closest to FDA approval?

It puts Insilico closest by trial stage, not necessarily closest to a U.S. FDA approval. Rentosertib is the most advanced human drug tied explicitly to aging biology, but its Phase 3 runs in China.

Rentosertib is an oral TNIK inhibitor for idiopathic pulmonary fibrosis, a progressive lung disease that becomes much more common with age. Insilico originally identified TNIK through its AI drug-discovery platform using disease and aging-related biological data.

On 10 September 2026, Insilico dosed the first patient in GENESIS-IPF-3, a 52-week Phase 3 trial expected to enroll 320 patients across 47 centers in China. Insilico says it could take three to four years from the start of Phase 3 to approval under favorable conditions. That puts it one full clinical stage ahead of Longeveron, Calico, BioAge and the better-known cellular-rejuvenation startups. A full clinical stage between Insilico and the rest is a big gap, and we look at how far the challengers trail in our report on longevity.

The U.S. picture is less clear. Rentosertib has had FDA Orphan Drug Designation for IPF since 2023, but no U.S. Phase 3 or agreed U.S. registration path has been disclosed. A Chinese trial may support a Chinese approval first.

The biological-age analysis keeps the program interesting for longevity. Researchers applied six proteomic aging clocks to samples from the Phase 2 trial and reported that all six shifted toward a younger predicted biological age in patients receiving the drug. Those clocks have no role as validated surrogate endpoints, so the FDA would still judge rentosertib only on lung disease.

Insilico is usually described as an AI drug-development company rather than a pure longevity biotech. If readers accept it inside the category, it leads the human race on stage, with a clear asterisk on geography.

Does Calico’s FDA Breakthrough plus EMA PRIME status put it in front?

It puts Calico in the front group. Fosigotifator now has strong regulatory support on both sides of the Atlantic, but the clinical evidence is still Phase 1b/2.

Calico was founded around the biology of aging, yet for years its clinical position looked less advanced than its reputation and funding suggested. That changed when the FDA gave fosigotifator Breakthrough Therapy Designation in June 2026, and again when Calico said in October 2026 that the European Medicines Agency had granted PRIME designation based on preliminary Phase 1b/2 data.

The drug activates eIF2B and is being tested in a Phase 1b/2 study in adults, children and infants with Vanishing White Matter disease, a rare progressive neurological disorder with no approved disease-modifying treatment.

Both designations require early clinical evidence that a therapy may offer a major improvement for a serious condition. Neither is an approval, and Calico has not disclosed a marketing application. But rare neurological diseases can follow short development paths when patient numbers are small and the treatment effect is large.

Calico’s previous experience also gives us a reason to stay cautious. Fosigotifator was studied in ALS through the HEALEY platform trial and failed to show a statistically significant benefit on the main disease-progression endpoint. The VWM biology and patient population are different, so the ALS failure does not settle the VWM question.

Today, Calico has the cleanest regulatory momentum of any human longevity company, even if Insilico is further along on stage.

Is BioAge close to an FDA approval now?

No. BioAge has one of the stronger clinical pipelines in longevity biotech today, but BGE-102 still needs to prove that its impressive biomarker effect translates into meaningful patient benefit.

BioAge develops drugs by studying the biology of human aging and identifying pathways associated with healthier or less healthy aging trajectories. Its current lead asset, BGE-102, inhibits NLRP3, an inflammatory pathway increasingly linked to cardiovascular, metabolic and retinal disease.

The Phase 1 numbers were striking. BioAge reported median reductions of at least 85% in high-sensitivity C-reactive protein at its 60-milligram and 120-milligram once-daily doses. The company also reported good tolerability across the tested dose levels.

BioAge’s Phase 2 cardiovascular study, QUELL-CV, has completed enrollment, with topline data expected in the second half of 2026. Its primary endpoint is change in hsCRP, and it is designed to help pick a Phase 3 dose. In September 2026, BioAge also dosed the first participant in QUELL-DME, a Phase 2 trial of about 180 people with diabetic macular edema, with results expected in the second half of 2027.

A large reduction in an inflammatory biomarker can make the mechanism look compelling without proving that patients experience fewer cardiovascular events or better vision. BioAge still needs that clinical proof before an FDA approval path becomes concrete.

How far behind are Cambrian and the other clinical longevity biotechs?

Cambrian, Rubedo and Juvenescence have become credible human-stage longevity companies, but none is currently close enough to an FDA filing to challenge the leaders.

Cambrian’s ATX-304 produced encouraging Phase 1b data in 23 adults with obesity and prediabetes. The company reported improvements in liver fat, visceral fat, triglycerides, adiponectin and resting metabolic rate after eight weeks. Phase 2 studies are still planned rather than running.

Cambrian also received up to $30.8 million from ARPA-H to advance its TORnado selective mTORC1 program. That program is even closer to classic geroscience because mTOR is one of the best-established aging pathways in experimental biology, but its regulatory development is earlier. ARPA-H funding is one source of money among many, and we cover who is funding whom in our longevity report.

Rubedo has generated one of the more interesting recent human datasets. Its RLS-1496 program entered Phase 1b/2a testing, and the company reported a 46% reduction in actinic keratosis lesions after four weeks in preliminary results. Counting skin lesions directly gives Rubedo a more concrete early efficacy measure than many biomarker-heavy longevity studies.

Juvenescence has also taken MDI-2517, a PAI-1 inhibitor, through Phase 1 and toward proof-of-concept development.

All three are past the purely preclinical stage. What separates them from Calico, Insilico and Longeveron is the lack of a late-stage trial, a major regulatory designation or a mature registrational discussion.

Company	Recent human evidence	Next real test
BioAge	BGE-102 cut hsCRP by ≥85% at key doses in Phase 1	QUELL-CV Phase 2 readout, then QUELL-DME
Cambrian	ATX-304 showed metabolic changes in 23 Phase 1b participants	Larger Phase 2 studies
Rubedo	RLS-1496 reported 46% AK lesion reduction at four weeks	Confirm effect in larger controlled cohorts
Juvenescence	MDI-2517 completed Phase 1 development	Phase 2 efficacy
Longeveron	Phase 2b missed primary endpoint; fewer cardiac events reported	FDA view on secondary data; funded Alzheimer’s trial

Are Life Biosciences and Retro actually close to FDA approval yet?

No. Life Biosciences and Retro have both reached human testing, but their lead programs are still near the beginning of clinical development.

Life Biosciences crossed an important line when the FDA cleared its IND for ER-100 and the company dosed the first participant in 2026. ER-100 uses controlled expression of OCT4, SOX2 and KLF4 to push aged retinal cells toward younger patterns of gene expression.

This is the first in-vivo partial epigenetic-reprogramming therapy to reach human testing. The study plans up to about 18 participants with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy. In October 2026, Life reported the first data: ER-100 was well tolerated through Day 56 in three glaucoma patients, with no serious adverse events, and two showed early visual-field improvements. A safety board recommended moving to the next dose. Three uncontrolled patients are a signal, not proof of efficacy.

Retro Biosciences entered the clinic through a different route. It dosed the first participant with RTR242 in Australia in late 2025. The oral small molecule is designed to improve lysosomal function and autophagy, the cellular recycling process that removes damaged proteins and other waste.

Retro’s first study is in healthy volunteers and focuses mainly on safety, tolerability and exploratory biomarkers. Company executives have said the study has progressed without dose-limiting toxicities so far, which is encouraging but still far from evidence that RTR242 can slow Alzheimer’s disease.

Life Biosciences therefore has the more direct rejuvenation experiment, while Retro has the simpler oral-drug format and a large funding base. Both still need controlled human efficacy data before FDA approval becomes a serious near-term question.

Why is NewLimit still far from FDA approval after raising $435 million?

NewLimit remains preclinical, so its enormous funding round says much more about investor confidence than about proximity to FDA approval.

The company raised $435 million in 2026 at a reported valuation of roughly $3.1 billion, one of the largest private financings in the longevity sector. Its technology uses epigenetic reprogramming to restore youthful functions in old cells without pushing them all the way back into pluripotency.

NewLimit has made real technical progress. It narrowed its first clinical effort around liver biology and, in an October 2026 update, said it had scaled up manufacturing and run its first large-animal studies. That update did not report human dosing. The company said earlier in 2026 that it expected to start human testing in 2027.

Before approval becomes a serious conversation, NewLimit still has to finish preclinical safety work, clear the regulatory process needed to dose humans, establish tolerability, identify an appropriate dose, show an efficacy signal and then run later-stage studies.

Altos Labs sits even further from a public approval race. Despite billions of dollars in initial funding and some of the best-known scientists in rejuvenation research, Altos has yet to disclose a human therapeutic program comparable with Life Biosciences’ ER-100.

Could one rare-disease trial unexpectedly win the longevity FDA race?

Yes. Rare diseases create the clearest path for an earlier-stage longevity company to jump several places in the ranking.

Calico’s fosigotifator is the clearest example today. Vanishing White Matter disease has no approved disease-modifying therapy, the patient population is small, and the drug now has both FDA Breakthrough Therapy and EMA PRIME support. If the ongoing Phase 1b/2 study produces a large, consistent clinical effect, Calico could move into registrational discussions much faster than a Phase 1b/2 label normally implies.

Longeveron tried the same regulatory shortcut through rare pediatric heart diseases. Laromestrocel carries Orphan Drug, Fast Track and Rare Pediatric Disease designations in HLHS. Its pediatric dilated cardiomyopathy program has also been structured around a direct move into a registrational Phase 2 study, subject to financing.

These programs show why a simple phase ranking can fail. A 30- or 40-patient rare-disease study with dramatic hard outcomes can sometimes create more regulatory leverage than a much larger mid-stage study in obesity or Alzheimer’s disease.

Longeveron’s HLHS experience also shows the limit of that shortcut: once the FDA rejected the endpoint and the trial then missed it, a supposedly short route turned into a negotiation over secondary data.

Has any aging-related biotech already received FDA approval?

Yes, and Stealth BioTherapeutics shows what the first wave of aging-biology approvals may look like: a mechanism associated with aging reaches the FDA through a tightly defined disease.

The FDA granted accelerated approval to elamipretide, marketed as Forzinity, for Barth syndrome. Elamipretide acts on mitochondrial biology, an area heavily studied in aging because mitochondrial dysfunction accumulates across many age-related conditions.

Barth syndrome, however, is a rare inherited mitochondrial disease that often begins in childhood. Stealth developed elamipretide as a mitochondrial-disease therapy rather than as a medicine intended to extend lifespan. Approval for a rare disease is no proof of lifespan benefit; we look at who has real data and who only promises in our report on longevity.

That makes Forzinity a useful precedent without making it an “anti-aging drug.” No drug has been approved for aging reversal or lifespan extension.

Insilico could eventually follow a similar route through pulmonary fibrosis. Calico could do it through Vanishing White Matter disease, and Longeveron through a pediatric heart disease or Alzheimer’s. Life Biosciences is attempting it through optic neuropathies.

Which longevity company is closest to FDA approval right now?

Loyal is closest if dog longevity counts. For humans, no company has a clear lead: Insilico is furthest along by stage, Calico has the strongest rare-disease regulatory signals, and Longeveron has dropped back after ELPIS II.

Longeveron no longer wins the narrow human-longevity definition by default. It still has the most randomized Phase 2 data among pure-plays and five FDA expedited or special designations across its programs. But ELPIS II missed its primary endpoint in September 2026, and its case now rests on secondary cardiac-event results the FDA has yet to weigh.

Its finances add a second layer of doubt. Longeveron is in a strategic review, has cut costs and hired an advisor to explore a possible business combination. The Alzheimer’s program has a clear Phase 2/3 design discussed with the FDA, but no one has yet committed to fund it.

Calico now sits in the front group. Fosigotifator’s FDA Breakthrough Therapy Designation and October 2026 EMA PRIME designation in Vanishing White Matter disease give it a rare-disease route that could accelerate sharply if the Phase 1b/2 results are strong.

Insilico is further ahead in conventional drug development. Rentosertib started Phase 3 for idiopathic pulmonary fibrosis in September 2026 and has human proteomic-aging data layered onto its program. Two things stop us calling it the straightforward winner: the trial is in China, with no U.S. registration path disclosed, and the company is primarily an AI drug developer rather than a longevity pure-play.

And Loyal remains in a league of its own on sheer regulatory distance. LOY-002 has satisfied two of the three big technical sections required for FDA expanded conditional approval. If the remaining manufacturing work clears review, the first FDA-authorized drug sold with an explicit healthy-lifespan goal may arrive for dogs well before humans.

Definition of “longevity company”	Closest company today	Why
Any longevity drug, including animals	Loyal	LOY-002 has cleared 2 of 3 major conditional-approval sections
Human pure-play longevity company	No clear leader (Calico, Longeveron)	Calico has the stronger designations; Longeveron more data but a missed primary endpoint
Broad human aging-biology company	Insilico Medicine	Rentosertib is in Phase 3, in China
Most likely rapid challenger	Calico	FDA Breakthrough and EMA PRIME status in a rare disease could compress development
Most advanced cellular rejuvenation company	Life Biosciences	First partial epigenetic-reprogramming therapy dosed in humans, with first data in three patients

So the direct answer today is Loyal for any FDA-authorized longevity product, and an open race for humans, with Calico and Insilico slightly ahead of a weakened Longeveron.

Human aging itself remains much further away. The first successful longevity biotech will almost certainly reach pharmacies through a disease label first, and only later will we have enough evidence to decide whether the medicine changes how humans age.